TickerTalks
Browse all tickers →
TickerTalks›$LAB
LALAB

Standard BioTools Inc.

$LAB·$340M·Medical - Equipment & Services·Healthcare
$0.65+1.3%YTD-35.4%1Y-50.2%
Mentions · last 7 days
2026-08-21: 692 posts2026-08-22: 603 posts2026-08-23: 433 posts5,368-6%
Price updated 1m ago·X counts updated 8d ago
LALAB
$LABStandard BioTools Inc.
$0.65+1.26%5.4k posts-6%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $LAB, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-31

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

A sub-dollar life-sciences microcap trying to reshape itself into an oncology bet — with a Nasdaq delisting notice as the clock ticking underneath.

Standard BioTools makes lab instruments used in proteomics and genomics research (mass cytometry, spatial biology, high-throughput qPCR). It just sold the mass cytometry business, cashed a $30M royalty-termination check from Illumina, and announced a merger with private oncology company Treeline Biosciences — while carrying a Nasdaq minimum-bid-price notice.

  • The standalone business is shrinking: recent quarters ran down 3-57% year-over-year with operating margins in the -45% to -120% range, so the run-it-alone story is genuinely broken — the asset sale and merger exist precisely because the standalone plan didn't work.
  • The Treeline merger is the actual bet: without a disclosed exchange ratio or clarity on Treeline's oncology pipeline economics, holders own an option on the combined entity, not on today's lab-instruments business — a very different investment than what the ticker looks like on the surface.
  • The listing cliff is real: at $0.64 the shares sit 1.5% off the 52-week low and Nasdaq sent the July 22 minimum-bid-price notice — the merger closing or a reverse split is what pulls the equity back over the listing bar within the standard 180-day cure window.
  • Insider action is only tax-withholding (F-InKind) share surrenders — that's people meeting an obligation, not conviction; there's no open-market buying to lean on.

The path if it works runs through the merger closing with a survivable exchange ratio and Treeline's oncology pipeline actually being valuable — then the equity re-rates as a new company and the listing question resolves. The path if it doesn't is the merger falling apart or closing on terms holders don't like, with the delisting clock still counting.

What to watch: The Treeline merger exchange ratio (when disclosed) and any Nasdaq listing-cure action — the two dated levers that decide whether this equity survives in a recognizable form.

On the calendar: 2026-11-03 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment17 posts analyzed · as of 2026-08-30

The LAB thread is dominated by crypto promoters flagging a falling-channel breakout on Binance, a bullish structure with '+100% mid-term potential,' repeated 'next 20X-50X gem' framing next to MANTRA and RIVER, and one 'Nostalgia. LAB' post. A candid skeptic warns of a 'scam pump' coming so early participants can dump higher, and open-interest data shows shorts at $4.88M against $2.49M longs with 78% of shorts profitable versus 13% of longs. Substantive analysis is thin.

Read the AI verdict + X sentiment for $LAB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Life science tools company offering microfluidics and mass cytometry instruments for drug discovery research.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Equipment & Services sits in its cycle right now — and what that implies for $LAB.

Medical - Equipment & Services · Healthcare

Hospital utilization recovery post-COVID is sustaining equipment demand; GLP-1 weight-loss drugs are a long-term volume headwind for bariatric equipment. Imaging and monitoring technology upgrades are driven by value-based care reimbursement incentives.

What this means for $LAB

Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; Standard BioTools Inc.

Top industry ETF

$IHIiShares U.S. Medical Devices ETF
-13.0%YTD
-10.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-7.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-91.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-21.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-20.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
48.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.07$-0.01-449.0%
Q1 2026May 5, 2026$-0.02$-0.020.0%
Q4 2025Feb 24, 2026$0.06$-0.03+300.0%
Q3 2025Nov 4, 2025$-0.09$-0.04-107.7%
Next earningsTue, Nov 3·consensus EPS $-0.02

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$21.1M+4.6%53.5%-44.5%$-0.12$-47.2M
Q4 FY25$23.8M-49.1%43.0%-92.1%$0.05$-1.7M
Q3 FY25$19.6M-56.5%48.5%-120%$-0.09$-23.1M
Q2 FY25$21.8M-3.2%48.8%-109%$-0.09$-22.6M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$82.5M$81.9M – $83.0M-$0.03-$0.03 – -$0.031
FY27$84.1M$83.5M – $84.7M-$0.09-$0.09 – -$0.091
FY28$88.0M$87.4M – $88.6M-$0.08-$0.08 – -$0.081
FY29$89.4M$88.8M – $90.0M-$0.15-$0.15 – -$0.151

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.2%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-19.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-40.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 42.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.405-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 22 other (10 inkinds · 10 awards · 2 exempts) in window

See when $LAB insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Standard BioTools Inc. (LAB) reported Q2 2026 financial results on 2026-08-05, reporting results detailed in attached press release. Management guidance: Outlook” and “About Standard BioTools Inc. Additional items: Item 7.01. Quarterly earnings are a material disclosure; investors should review the full press release for segment details and management commentary.

8-KMaterial agreementJul 288-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

Standard BioTools Inc. (LAB) entered into a Termination, Waiver and Release Agreement with Illumina, Inc. on July 24, 2026, receiving approximately $30 million in cash in exchange for waiving and releasing future earnout and royalty payment obligations related to SomaScan assay services, SOMAmer-based array kits, and next-generation sequencing library prep kits. The related royalty and license agreements (from January 30, 2026 in connection with Illumina's purchase of the SomaScan business) were also terminated. Receiving $30M upfront to terminate future contingent revenue streams represents a risk/liquidity trade-off; the materiality depends on how probable those future royalties were.

8-KListing / delisting noticeJul 248-K — Item 3.01: Listing / delisting notice
AI summary

LAB filed an 8-K covering Item(s) 3.01. Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On July 22, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global Select Market. . Investors should review the full filing for complete details.

8-KOfficer or director changeJun 188-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Standard BioTools (LAB) held its 2026 Annual Meeting on June 17, 2026 with 390,368,119 shares outstanding. Shareholders approved a new 2026 Equity Incentive Plan and an amendment to the Employee Stock Purchase Plan adding 1,200,000 shares in aggregate. Routine director elections and other governance proposals also passed. No extraordinary compensation or structural changes were disclosed.

SC 13DActivist position (5%+)Jun 12SC 13D
AI summary

Viking Global Investors LP filed an initial Schedule 13D on Standard BioTools Inc. (LAB) as of June 6, 2026, disclosing beneficial ownership of approximately 39,296,310 shares representing 15% of the class (via Viking Global Investors LP) and 10.1% (via the Viking Global Opportunities sub-entities). An initial 13D (rather than passive 13G) from a major hedge fund signals active engagement intent — Viking may seek to influence strategy, governance, or M&A at the life-science tools company.

SC 13D/AActivist amendmentJun 9SC 13D/A
AI summary

Casdin Capital, LLC (investment adviser) filed Amendment No. 8 to Schedule 13D on June 9, 2026, disclosing a 22.7% aggregate beneficial ownership stake (88,783,856 shares) in Standard BioTools Inc. (LAB) as of June 6, 2026. The group includes Casdin Partners Master Fund, Casdin Private Growth Equity Fund II (3.6%), and related entities. The filing is an amendment reflecting updated share counts; at 22.7% with shared voting and dispositive power, Casdin remains the dominant activist/strategic holder and any position changes or engagement disclosures would be highly material to LAB.

8-KMaterial agreementJun 88-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 5.01: Change in control · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

LAB (LAB) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The company announced the appointment of a new officer or director to a senior leadership position. Individuals named in the filing include Standard Bio, Tools Inc. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeJun 38-K — Item 5.02: Officer or director change
AI summary

Standard BioTools Inc. (LAB) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in Chief Financial Officer. Individuals named in the filing include Standard Bio, Tools Inc. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

+ 25 other (5 13Gs · 5 425s · 3 8-Ks · 2 S-8s) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Standard BioTools Reports Second Quarter 2026 Financial Resultsglobenewswire.com·26d agoStandard BioTools Reports Second Quarter 2026 Financial Resultsglobenewswire.com·26d agoStandard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciencesglobenewswire.com·34d agoStandard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026globenewswire.com·41d agoAre DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?gurufocus.com·41d ago

More in Medical - Equipment & Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$HIMS$LNSR$OMCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport